PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1756-8722

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy ; volume:10 ; number:1 ; day:3 ; month:8 ; year:2017 ; pages:1-21 ; date:12.2017
Journal of hematology & oncology ; 10, Heft 1 (3.8.2017), 1-21, 12.2017

Keyword: Krebs
Onkologie

Creator: Long, Junyu

Contributor: Lin, Jianzhen
Wang, Anqiang
Wu, Liangcai
Zheng, Yongchang
Yang, Xiaobo
Wan, XueShuai
Xu, Haifeng
Chen, Shuguang
Zhao, Haitao
SpringerLink (Online service)

DOI: 10.1186/s13045-017-0511-2

URN: urn:nbn:de:1111-2017101913238

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:22 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Long, Junyu
Lin, Jianzhen
Wang, Anqiang
Wu, Liangcai
Zheng, Yongchang
Yang, Xiaobo
Wan, XueShuai
Xu, Haifeng
Chen, Shuguang
Zhao, Haitao
SpringerLink (Online service)

Other Objects (12)

WNT/β-catenin regulatory roles on PD-(L)1 and immunotherapy responses

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers

Hochschulschrift

Regulation of PD-L1 by PPARg for immunotherapy in gastrointestinal cancers

Regulatory mechanisms of PD-1/PD-L1 in cancers

Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma

Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers : the “all-around warrior” in immunotherapy

Correction: Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers: the “all-around warrior” in immunotherapy

Role of the PD-1/PD-L inhibitory pathway during experimental infection by Trypanosoma cruzi Tulahuen strain

Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study

First-line hepatic arterial infusion chemotherapy plus lenvatinib and PD-(L)1 inhibitors versus systemic chemotherapy alone or with PD-(L)1 inhibitors in unresectable intrahepatic cholangiocarcinoma

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

WNT/β-catenin regulatory roles on PD-(L)1 and immunotherapy responses

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers

Hochschulschrift

Regulation of PD-L1 by PPARg for immunotherapy in gastrointestinal cancers

Regulatory mechanisms of PD-1/PD-L1 in cancers

Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma

Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers : the “all-around warrior” in immunotherapy

Correction: Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers: the “all-around warrior” in immunotherapy

Role of the PD-1/PD-L inhibitory pathway during experimental infection by Trypanosoma cruzi Tulahuen strain

Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study

First-line hepatic arterial infusion chemotherapy plus lenvatinib and PD-(L)1 inhibitors versus systemic chemotherapy alone or with PD-(L)1 inhibitors in unresectable intrahepatic cholangiocarcinoma

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

WNT/β-catenin regulatory roles on PD-(L)1 and immunotherapy responses

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers

Hochschulschrift

Regulation of PD-L1 by PPARg for immunotherapy in gastrointestinal cancers

Regulatory mechanisms of PD-1/PD-L1 in cancers

Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma

Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers : the “all-around warrior” in immunotherapy

Correction: Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers: the “all-around warrior” in immunotherapy

Role of the PD-1/PD-L inhibitory pathway during experimental infection by Trypanosoma cruzi Tulahuen strain

Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study

First-line hepatic arterial infusion chemotherapy plus lenvatinib and PD-(L)1 inhibitors versus systemic chemotherapy alone or with PD-(L)1 inhibitors in unresectable intrahepatic cholangiocarcinoma

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy

Object Details

References and Relationships

Classification and Topics

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

WNT/β-catenin regulatory roles on PD-(L)1 and immunotherapy responses

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers

Regulation of PD-L1 by PPARg for immunotherapy in gastrointestinal cancers

Regulatory mechanisms of PD-1/PD-L1 in cancers

Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma

Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers : the “all-around warrior” in immunotherapy

Correction: Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers: the “all-around warrior” in immunotherapy

Role of the PD-1/PD-L inhibitory pathway during experimental infection by Trypanosoma cruzi Tulahuen strain

Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study

First-line hepatic arterial infusion chemotherapy plus lenvatinib and PD-(L)1 inhibitors versus systemic chemotherapy alone or with PD-(L)1 inhibitors in unresectable intrahepatic cholangiocarcinoma

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

WNT/β-catenin regulatory roles on PD-(L)1 and immunotherapy responses

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers

Regulation of PD-L1 by PPARg for immunotherapy in gastrointestinal cancers

Regulatory mechanisms of PD-1/PD-L1 in cancers

Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma

Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers : the “all-around warrior” in immunotherapy

Correction: Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers: the “all-around warrior” in immunotherapy

Role of the PD-1/PD-L inhibitory pathway during experimental infection by Trypanosoma cruzi Tulahuen strain

Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study

First-line hepatic arterial infusion chemotherapy plus lenvatinib and PD-(L)1 inhibitors versus systemic chemotherapy alone or with PD-(L)1 inhibitors in unresectable intrahepatic cholangiocarcinoma

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

WNT/β-catenin regulatory roles on PD-(L)1 and immunotherapy responses

Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers

Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers

Regulation of PD-L1 by PPARg for immunotherapy in gastrointestinal cancers

Regulatory mechanisms of PD-1/PD-L1 in cancers

Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma

Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers : the “all-around warrior” in immunotherapy

Correction: Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers: the “all-around warrior” in immunotherapy

Role of the PD-1/PD-L inhibitory pathway during experimental infection by Trypanosoma cruzi Tulahuen strain

Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study

First-line hepatic arterial infusion chemotherapy plus lenvatinib and PD-(L)1 inhibitors versus systemic chemotherapy alone or with PD-(L)1 inhibitors in unresectable intrahepatic cholangiocarcinoma

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Related objects

Reset password